Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by OttawaPeteron Feb 01, 2023 4:45pm
111 Views
Post# 35260698

RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!

RE:RE:RE:RE:RE:RE:Jannsen Biotech extends its partnership with BTI on xB3!!

Boomskid wrote: I suspect, OttawaPeter, or at least it wouldn't surprise me, that some deals are still available for closing and/or extending.

My guess is that for many months Bioasis, Midatech, Ladenburg Thalmann and other players demanded a standstill of some sort. That could mean that Bioasis could not close anything during that time because it would have changed Bioasis's market cap and potential commercial value. That would have changed valuations as defined in the "Arrangement" and it very well could have changed some private plans.

Also, as the Information Circular and Evens & Evans discussed, Bioasis management may have  had conflicts of interest such that they had no reason to advance or even promote Bioasis and its development projects. I've been posting my worries about that for over a year. Where did xB3 go? What was the real reason for acquiring Cresence?

If any of this is so, then there may be deals just waiting to get done, and others waiting to be extended.

What was Ellipses, anyway? It sure looked real in the corporate presentation that got loose.

jd


 

EXACTLY

<< Previous
Bullboard Posts
Next >>